1 / 36

IBD UPDATE 2007

IBD UPDATE 2007. DR STEPHEN BURMEISTER Gastroenterologist North Shore Hospital. Hot Topics . Crohns treatment – Infliximab Crohns genetics & IBD cancer risk 5 ASA drugs – reduce cancer risk, needed in higher doses in U.Colitis Actions of Aminosalicylates Effect of smoking on IBD

braden
Download Presentation

IBD UPDATE 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IBD UPDATE 2007 DR STEPHEN BURMEISTER Gastroenterologist North Shore Hospital

  2. Hot Topics • Crohns treatment – Infliximab • Crohns genetics & IBD cancer risk • 5 ASA drugs – reduce cancer risk, needed in higher doses in U.Colitis • Actions of Aminosalicylates • Effect of smoking on IBD • Azathioprine monitoring with 6TGN & TPMT

  3. Recent Questions 2003 • A 54 year old man with colonic Crohns is in remission after an 8wk course of prednisone. Which Rx is most likely to maintain remission? • Salazopyrin • Prednisolone • Azathioprine • Metronidazole • Methotrexate

  4. Recent Questions • A 45 year old with Crohns presents with fever, rigors & RLQ pain. Meds include Pred 10mg & Sulphasalazine. Temp 37.8, very tender RLQ but no general peritonitis. CT abdo shown. Best initial Rx? • IV Abs, IV hydrocortisone & IV Abs, Laparotomy, IV hydrocort only, Change sulphasalazine.

  5. Recent Questions 3 • A 43 year old man 6/12 post resection 50cm terminal ileum for Crohns presents with diarrhoea & abdo pain. Examination and tests normal including colonoscopy. Best treatment? • Codeine, High fibre diet, Cholestyramine, Sulphasalazine, Prednisolone.

  6. IBD pathogenesis • IBD is a cycle of inflammation, repair and healing • Probably as a result of inappropriate immune perception of normal gut flora • As SES rises, IBD rates rise – probably due to reduced exposure to infections in childhood • Also a genetic component present

  7. Rising incidence of Crohns

  8. Stable incidence of UC

  9. Geographical distribution of UC

  10. Crohns Genetics • First genetic susceptibility factor found: • CARD15/NOD 2 gene mutations on Chrom 16 • A toll-like receptor involved in sensing the bacterial environment • Present in 20% Crohns patients, but not in UC • Phenotypic link to ileal disease +/- fistulae • Twins 58% concordance in Crohns

  11. Infliximab in Crohns • What is infliximab? • Anti – TNF alpha chimeric antibody • Safe and effective for refractory chronic active and fistulous Crohns disease • Expensive, but saves money on later hospital/surgical care • Increases the risk of infections (esp. Tb) and possibly lymphoproliferative disorders

  12. Safety profile • Antibody formation 13% (anti HACA) • Infusion reactions in 17%, but only 0.5% are serious • Anti – dsDNA antibodies develop in 9% • Schiabe T. Can J Gastroent 2000; 14: 29

  13. Important papers 1 • Targan S et al, NEJM 1997; 337: 1029-35 • First placebo controlled trial • 65% of chronic CD patients healed up vs. 17% placebo response • 5mg/kg dose appeared best

  14. Important papers 2 • Present DH et al, NEJM 1999; 340: 1398-1404 • Second placebo trial, in patients with fistulising disease • 55% closure of fistulas vs. 13% placebo • All responders by time of second infusion • Median duration of response 3 months

  15. Important papers 3 • Rutgeerts P et al, Gastroenterology 1999; 117: 761-9 • Longer term study looking at retreatment • 73 patients who had maintained response at 8weeks rerandomised to further infusions or placebo • 53% patients in remission vs. 13% placebo • Benefit maintained for 44 weeks • Those on 6MP had a 75% response

  16. Important papers 4 • Accent 1: Hanauer S et al, Lancet 2002; May 4:359(9317)1541-9 573pts • Non fistulising CD ongoing Rx – 83% respond, but only 1/3 were on Aza/6MP • 32% infections needing Abs, 3.8% serious • 10>5mg/kg dosing 8weekly • Overall Tb rate ~100/170,000 pts with at least 14 deaths

  17. Important papers 5 • Accent 2: Sands B et al, NEJM 2004 Feb 26; 350(9)876-85 • IFB for maintenance in fistulising CD • 64% response • Response duration 40 v 14 weeks for the ongoing treatment

  18. Other important papers • Cohen RD. Am J Gastroent 2000; 95: 3469-77. 129 patients, 65% luminal, 78% fistulas respond. 54% off steroids • Rutgeerts P. NEJM 2005; 353: 2467-76 ACT 1 & 11 trials in 728pts showed 70% response to 0,2,6wkly Infliximab infusions in mod/severe UC at week 8 and 45% response at 1year to 8weekly infusions

  19. Extra-Colonic Features • Related or not to disease activity • Joints • Arthropathies – small and large joint (SI) • Ankylosing spondylitis • Eyes - uveitis and episcleritis • Skin -erythema nodosum pyoderma gangrenosum • Sclerosing cholangitis • Cholestatic LFTs • Renal amyloid (rare) • Venous and arterial thromboembolism • Earlier treatment with steroids +/- infliximab

  20. Aminosalicylate actionsare Chemopreventative • Inhibit leucotriene, PG and cytokine synthesis • Scavenge oxygen free radicals • Induce apoptosis & aid DNA mismatch repair • Impair WBC adhesion & function • Mesalazine any dose reduces dysplasia/CRC in IBD • Lab data - reduces spontaneous mutation rate by70%

  21. 5 ASA drugs • Reduce the long term risk of cancer in Crohns Eaden et al Aliment Pharm Ther 2000; 14: 145-33 • No role in keeping remission in CD post operatively over 18months except in a subgroup of patients with only small bowel disease • This is in contrast to earlier trials • Lochs H et al, Gastroenterology 2001; 118: 264-273 • Hanauer S et al, Clin.Gastro.Hepatol. 2004; May(5):379-88

  22. Crohns post surgery • Recurrence is high – 50% symptomatic, 80% radiologic/endoscopic at 3years • These patients were on no treatment • Therefore put higher risk patients (smokers, perforating disease, repeat surgery & ileocolonic anastomosis) onto Azathioprine/ 6MP • McLeod RS. et al, Gastroenterology 1997; 113: 1823-27

  23. CRC risk in IBD • Ulcerative colitis: with PSC is highest risk • Pancolitis 2.4RR, cumulative incidence 5-10% after 20years (i.e. 0.5%/yr) • Left sided colitis - risk is delayed by a decade • Proctitis - no increased cancer risk • Crohns colitis is probably similar but data is limited.

  24. Nicotine • Smoking lessens risk of UC by 40% • Crohns disease is 2-4 times more common in smokers than non-smokers • Relapse rate decreases by 40% in CD patients who stop smoking • Need for steroids and immunosuppressives increases in smokers (i.e. more steroid dependence) • Cosne et al, Gastroenterology 2001; 120: 1093-99

  25. Ulcerative colitis • Use higher doses aminosalicylates to treat flares (2.4-4.8g/day) • Meta-analysis of placebo controlled trials show odds ratio for remission with doses <2g/day, 2-3g/day & >3g/day were 1.5, 1.9, 2.7 respectively • No clear dose response with maintenance mesalazine treatment • Topical ASA drugs are more effective than topical steroids for active distal disease

  26. UC – What doesn’t work? • Rectal steroid is not as good as rectal mesalazine for remission in flares of left sided UC (Lee FL et al, Gut 1996; 38: 229-33) • Steroids do not maintain remission therefore avoid long term use • Antibiotics/Heparin/Probiotics unproven

  27. CD - What doesn’t work? • Steroids have no maintenance benefit in Crohns (Steinhart AH et al, Cochrane Library, issue 3, 2000) • This includes budesonide (Gross V et al Gut 1998; 42: 493-6) • Cyclosporin doesn’t help in Crohns • NSAIDs also worsen the disease • Probiotics unproven

  28. Mesalazine in Crohn’s • Initial reports showed a benefit • Sulfasalazine 3 – 6g daily effective in ileal, ileocolic, colonic • Asacol 3.2 g/day effective in ileocolic or colonic • Pentasa 4g/day effective in ileal, ileocolic, colonic • 2004 meta-analysis, 615 patients 3 RCTs of Mesalazine1 • CDAI dropped 63 points vs 45 points for placebo (p = 0.04) • Better than placebo, but debatable clinical significance 1. Hanauer SB. Clin Gastro and Hepatol. 2004;2:379-88

  29. Other Therapies • Nicotine Patches • Effective in two RCTs of mild colitis • Ineffective as maintenance therapy • High incidence of side-effects • Aloe Vera Gel • 100ml bd for mild to moderate colitis • RCT: 30 treated vs 14 placebo • Clinical response 47% vs 14% (p < 0.05) • Histological score decreased significantly (p = 0.01) • $150 - $250 per month • slide courtesy Dr John Perry

  30. Probiotics in IBD • Probiotics are commensuals that benefit humans (e.g VSL3 treats pouchitis) • Prebiotics are foods that influence growth of certain gut organisms (e.g. oligosaccharides to treat Ab associated diarrhoea and reduce Cl.difficule relapse) • Probiotics are currently unproven in IBD

  31. ASCA & pANCA • Anti saccharomyces cerevisine antibodies • High specificity (over 95%) for Crohns disease, but not sensitive • Antigen is found in Bakers yeast • pANCA is more assoc with UC, but PPV is only 76% • At present these tests do not reliably predict how indeterminant colitis will proceed.

  32. Treatment of IBD in Pregnancy • Outcomes worse if active disease at conception • Aim to induce remission before conception • Risk to foetus if ongoing active disease • Most meds used in IBD are safe: • Mesalazine (C) • Corticosteroids (A) • Aza/6-MP (from transplant and AIH literature) (D) • Cyclosporin (C) (increased prematurity/low birth weight but high survival) • Infliximab (>250 births now – no increased risk) (C) • Metronidazole (B), Ciprofloxacin (B) • Budesonide (B3) • Contraindicated • Methotrexate (D) – spontaneous abortion and teratogenicity • Slide courtesy Dr John Perry Caprilli R. Gut 2006;55:36-58

  33. Summary Crohns vs UC • Mesalazine is less effective in Crohns • Steroids work in both but not long term • Azathioprine/6MP very effective in both • Antibiotics may help in active Crohns • Stopping smoking very impt in Crohns • Infliximab well established for induction and maintenance treatment of Crohns but only rescue therapy for UC • Elemental/polymeric diet can treat CD

  34. Azathioprine monitoring with6-TGN & TPMT • Thiopurine methyl transferase activity can be measured before starting treatment: Non-metabolisers should not have AZA/6MP Intermediate metabolisers start at 50% dose High metabolisers may need early dose increase 6-Thioguanine Nucleotide is the active metabolite of AZA/6MP, so levels can be measured to ensure peak activity without toxicity

More Related